Bortezomib with Dexamethasone in Newly Diagnosed Patients with Primary Systemic Light Chain Amyloidosis or Multiple Myeloma-Associated AL Amyloidosis

被引：1
|
作者：
Huang, Beihui [1 ]
Li, Juan [1 ]
Liu, Junru [1 ]
Zheng, Dong [1 ]
Chen, Mei [1 ]
Zhou, Zhenhai [1 ]
Xu, Duorong [1 ]
Zou, Waiyi [1 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou 510275, Guangdong, Peoples R China
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.5036.5036
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5036
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma
    Kawano, Yawara
    Hata, Hiroyuki
    Takashio, Seiji
    Tsujita, Kenichi
    Ueda, Mitsuharu
    Matsuoka, Masao
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (03) : E38 - E41
  • [2] Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis
    Kennedy, Vanessa E.
    Natsuhara, Kelsey
    Shah, Nina D.
    Arora, Shagun
    Wolf, Jeffrey
    Martin, Thomas G.
    Aras, Mandar A.
    Chung, Alfred
    Wong, Sandy W.
    CURRENT PROBLEMS IN CANCER, 2023, 47 (03)
  • [3] Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
    Kastritis, Efstathios
    Wechalekar, Ashutosh D.
    Dimopoulos, Meletios A.
    Merlini, Giampaolo
    Hawkins, Philip N.
    Perfetti, Vittorio
    Gillmore, Julian D.
    Palladini, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 1031 - 1037
  • [4] TREATMENT WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH LIGHT CHAIN AL AMYLOIDOSIS AND MULTIPLE MYELOMA
    Basset, M.
    Milani, P.
    Foli, A.
    Merlini, G.
    Palladini, G.
    HAEMATOLOGICA, 2018, 103 : 43 - 43
  • [5] Multiple myeloma-associated skin light chain amyloidosis: A case of misdiagnosis
    Xiao, Li
    Lin, Fengxia
    Xiao, Rong
    Hu, Chun
    Deng, Mingyang
    Li, Daiqiang
    She, Xiaoling
    Liu, Fuyou
    Sun, Lin
    ONCOLOGY LETTERS, 2016, 11 (06) : 3617 - 3620
  • [6] TREATMENT WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND LIGHT CHAIN (AL) AMYLOIDOSIS
    Milani, P.
    Basset, M.
    Russo, F.
    Bozzola, M.
    Foli, A.
    Palladini, G.
    Merlini, G.
    HAEMATOLOGICA, 2017, 102 : 272 - 273
  • [7] Unusual milia amyloidosis as initial signs of multiple myeloma-associated systemic amyloidosis
    Ohashi, Takenobu
    Kikuchi, Nobuyuki
    Yamamoto, Toshiyuki
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2013, 52 (08) : 981 - 982
  • [8] Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study
    Zhang, Yumeng
    Duncanson, Lauren
    Brayer, Jason
    Reu, Frederic
    Hansen, Doris
    Alsina, Melissa
    Nishihori, Taiga
    Ochoa-Bayona, Jose
    Liu, Hien
    Shain, Kenneth
    Thompson, Zachary
    Baz, Rachid
    Blue, Brandon
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (08): : E770 - E776
  • [9] Bortezomib Based Therapy for Newly Diagnosed Patients with Advanced Multisystem Light Chain Amyloidosis (AL)
    Maramattom, Leena Varkey
    Singh, Veerpal
    Cornell, Robert Frank
    Randhawa, Jasleen K.
    Thomas, Mathew
    Saad, Ayman A.
    Palmer, Jeanne
    Hari, Parameswaran
    BLOOD, 2011, 118 (21) : 821 - 821
  • [10] Multiple myeloma-associated light chain amyloidosis presenting as verrucous lingual masses
    Lee, KH
    Lee, JS
    Cho, YK
    Kim, SY
    Yoo, JY
    Park, CJ
    ACTA DERMATO-VENEREOLOGICA, 2005, 85 (05) : 447 - 448
12345